James J Dignam

Summary

Affiliation: University of Chicago
Country: USA

Publications

  1. pmc The use and interpretation of competing risks regression models
    James J Dignam
    Department of Health Studies, The University of Chicago, Chicago, Illinois 60637, USA
    Clin Cancer Res 18:2301-8. 2012
  2. ncbi request reprint Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer
    James J Dignam
    Department of Health Studies, 5841 South Maryland Ave, MC 2007, University of Chicago, Chicago, IL 60637, USA
    J Natl Cancer Inst 98:1647-54. 2006
  3. ncbi request reprint Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer
    James J Dignam
    Department of Health Studies, The University of Chicago, Chicago, IL 60637, USA
    Breast Cancer Res Treat 97:245-54. 2006
  4. pmc Choice and interpretation of statistical tests used when competing risks are present
    James J Dignam
    Department of Health Studies, The University of Chicago, Chicago, IL 60637, USA
    J Clin Oncol 26:4027-34. 2008
  5. pmc Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer
    James J Dignam
    Department of Health Studies, The University of Chicago, Chicago, IL 60637, USA
    Breast Cancer Res Treat 116:595-602. 2009
  6. pmc Estimating breast cancer-specific and other-cause mortality in clinical trial and population-based cancer registry cohorts
    James J Dignam
    Department of Health Studies and Cancer Research Center, The University of Chicago, Chicago, IL 60637, USA
    Cancer 115:5272-83. 2009
  7. ncbi request reprint The role of cancer cooperative groups within the spectrum of cancer care
    James J Dignam
    Department of Health Studies, The University of Chicago and University of Chicago Cancer Research Center, Chicago, IL 60637, USA
    Cancer Control 11:55-63. 2004
  8. ncbi request reprint Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer
    James J Dignam
    Department of Health Studies and Cancer Research Center, The University of Chicago, Chicago, IL 60637, USA
    J Natl Cancer Inst 95:1467-76. 2003
  9. ncbi request reprint Prognosis after rectal cancer in blacks and whites participating in adjuvant therapy randomized trials
    James J Dignam
    Department of Health Studies, University of Chicago and University of Chicago Cancer Research Center, Chicago, IL 60637, USA
    J Clin Oncol 21:413-20. 2003
  10. ncbi request reprint A missing data approach to semi-competing risks problems
    James J Dignam
    Department of Health Studies, The University of Chicago, Chicago, IL 60637, USA
    Stat Med 26:837-56. 2007

Research Grants

Detail Information

Publications29

  1. pmc The use and interpretation of competing risks regression models
    James J Dignam
    Department of Health Studies, The University of Chicago, Chicago, Illinois 60637, USA
    Clin Cancer Res 18:2301-8. 2012
    ..With competing risks, several modeling approaches are available to evaluate the relationship of covariates to cause-specific failures. We discuss the use and interpretation of commonly used competing risks regression models...
  2. ncbi request reprint Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer
    James J Dignam
    Department of Health Studies, 5841 South Maryland Ave, MC 2007, University of Chicago, Chicago, IL 60637, USA
    J Natl Cancer Inst 98:1647-54. 2006
    ..We investigated the association of body mass index (BMI) with outcomes after colon cancer in patients from cooperative group clinical trials...
  3. ncbi request reprint Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer
    James J Dignam
    Department of Health Studies, The University of Chicago, Chicago, IL 60637, USA
    Breast Cancer Res Treat 97:245-54. 2006
    ..Both obesity and estrogen receptor negative (ER-) tumors are more prevalent in black women than in whites in North America. We evaluated obesity and race in relation to outcomes in women with ER-breast cancer...
  4. pmc Choice and interpretation of statistical tests used when competing risks are present
    James J Dignam
    Department of Health Studies, The University of Chicago, Chicago, IL 60637, USA
    J Clin Oncol 26:4027-34. 2008
    ..We present simulation study results and discuss examples from cancer clinical trials to illustrate these points and provide guidance for analysis when competing risks are present...
  5. pmc Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer
    James J Dignam
    Department of Health Studies, The University of Chicago, Chicago, IL 60637, USA
    Breast Cancer Res Treat 116:595-602. 2009
    ..Examination of the magnitude and changes in the hazard of failure over time in node-negative breast cancer may also be informative in this regard...
  6. pmc Estimating breast cancer-specific and other-cause mortality in clinical trial and population-based cancer registry cohorts
    James J Dignam
    Department of Health Studies and Cancer Research Center, The University of Chicago, Chicago, IL 60637, USA
    Cancer 115:5272-83. 2009
    ..The authors of this report evaluated the performance of these estimates relative to a third approach based on detailed clinical follow-up history...
  7. ncbi request reprint The role of cancer cooperative groups within the spectrum of cancer care
    James J Dignam
    Department of Health Studies, The University of Chicago and University of Chicago Cancer Research Center, Chicago, IL 60637, USA
    Cancer Control 11:55-63. 2004
  8. ncbi request reprint Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer
    James J Dignam
    Department of Health Studies and Cancer Research Center, The University of Chicago, Chicago, IL 60637, USA
    J Natl Cancer Inst 95:1467-76. 2003
    ..We evaluated the association of obesity with outcomes and with tamoxifen efficacy in women with early-stage, hormone-responsive breast cancer participating in a multicenter cancer cooperative group clinical trial...
  9. ncbi request reprint Prognosis after rectal cancer in blacks and whites participating in adjuvant therapy randomized trials
    James J Dignam
    Department of Health Studies, University of Chicago and University of Chicago Cancer Research Center, Chicago, IL 60637, USA
    J Clin Oncol 21:413-20. 2003
    ..The randomized trial setting enhances uniformity in disease stage and treatment plan among all participants...
  10. ncbi request reprint A missing data approach to semi-competing risks problems
    James J Dignam
    Department of Health Studies, The University of Chicago, Chicago, IL 60637, USA
    Stat Med 26:837-56. 2007
    ..We apply the proposed method to the problem of estimating the distribution of time to tumour recurrence at specific sites among breast cancer patients participating in randomized clinical trials...
  11. doi request reprint Race and the prognostic influence of p53 in women with breast cancer
    Keith A Dookeran
    The Cancer Foundation for Minority and Underserved Populations, Chicago, IL, USA
    Ann Surg Oncol 19:2334-44. 2012
    ..We investigate whether the influence of p53 is unique to AAs or is present in other race/ethnic groups, and how this compares with known prognostic factors...
  12. pmc Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density
    Ningqi Hou
    Affiliations of authors Department of Health Studies NH, jjd, DH and Department of Medicine and Center for Clinical Cancer Genetics SH, OIO, University of Chicago, Chicago, IL Center for Injury Research and Prevention, Children s Hospital of Philadelphia, Philadelphia, PA WW
    J Natl Cancer Inst 105:1365-72. 2013
    ..Although studies have demonstrated a positive association between hormone replacement therapy (HRT) and breast cancer risk, this association may vary by patient factors...
  13. pmc Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma
    Zacariah E Labby
    Department of Radiology, The University of Chicago, Chicago, IL 60637, USA
    J Thorac Oncol 8:478-86. 2013
    ..Linear tumor thickness measurements, disease volume measurements, and lung volume measurements (a physiological correlate of disease volumes) were investigated in this study...
  14. pmc Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers
    Angela R Bradbury
    University of Chicago Center for Clinical Cancer Genetics, University of Chicago, Chicago, Illinois, USA
    Genet Med 10:161-6. 2008
    ..To evaluate prophylactic salpingo-oophorectomy uptake and timing among BRCA1/2 mutation carriers in a cancer risk assessment program...
  15. ncbi request reprint Colorectal cancer model of health disparities: understanding mortality differences in minority populations
    Blase N Polite
    Section of Hematology Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA
    J Clin Oncol 24:2179-87. 2006
    ..Finally, areas of ongoing and future research and policy initiatives aimed at reducing disparities are discussed...
  16. doi request reprint p53 as a marker of prognosis in African-American women with breast cancer
    Keith A Dookeran
    The Cancer Foundation for Minority and Underserved Populations, Chicago, IL, USA
    Ann Surg Oncol 17:1398-405. 2010
    ..We investigate the value of p53 status within the context of stage and intrinsic subtype classification (subtype), in a group of African-American (AA) women of lower socioeconomic status (SES) with primary breast cancer...
  17. ncbi request reprint Colorectal cancer and race: understanding the differences in outcomes between African Americans and whites
    Blase N Polite
    Section of Hematology Oncology, Department of Medicine, The University of Chicago Medical Center, 5841 South Maryland Avenue, MC 2115, Chicago, IL 60637 1470, USA
    Med Clin North Am 89:771-93. 2005
    ..The task now becomes to continue to understand the reasons for the disparities and ultimately to come up with workable solutions so that the amazing progress in CRC treatment benefits all groups in this country...
  18. pmc Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer
    Ezra E W Cohen
    Department of Medicine, University of Chicago, Chicago, IL, USA
    J Clin Oncol 28:3336-43. 2010
    ....
  19. pmc Optimization of response classification criteria for patients with malignant pleural mesothelioma
    Zacariah E Labby
    Department of Radiology, The University of Chicago, Chicago, IL 60637, USA
    J Thorac Oncol 7:1728-34. 2012
    ..The purpose of this work is to optimize the correlation between tumor response and patient survival by assessing the validity of existing response criteria in MPM and proposing alternative criteria...
  20. ncbi request reprint How often do BRCA mutation carriers tell their young children of the family's risk for cancer? A study of parental disclosure of BRCA mutations to minors and young adults
    Angela R Bradbury
    Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, IL, USA
    J Clin Oncol 25:3705-11. 2007
    ..Yet, many BRCA mutation carriers discuss their results with their children. This study describes the prevalence and experiences of parental communication of BRCA results to children under the age of 25 years old...
  21. ncbi request reprint MYC is amplified in BRCA1-associated breast cancers
    Tatyana A Grushko
    Section of Hematology Oncology, Department of Medicine, Committees on Genetics and Cancer Biology, University of Chicago, Chicago, Illinois 60637 1463, USA
    Clin Cancer Res 10:499-507. 2004
    ....
  22. ncbi request reprint Is patient travel distance associated with survival on phase II clinical trials in oncology?
    Elizabeth B Lamont
    Department of Medicine and Cancer Research Center, The University of Chicago, Chicago, IL, USA
    J Natl Cancer Inst 95:1370-5. 2003
    ..We hypothesized that this phenomenon, often called "referral bias" or "distance bias," may also be evident in curative-intent cancer trials at specialized cancer centers...
  23. pmc Diffusing capacity predicts long-term survival after lung resection for cancer
    Mark K Ferguson
    Department of Surgery, The University of Chicago, Chicago, IL, USA
    Eur J Cardiothorac Surg 41:e81-6. 2012
    ..Diffusing capacity (DLCO) is a predictor of complications after resection for lung cancer. We sought to determine whether DLCO is also prognostic for long-term survival after lung resection for cancer...
  24. ncbi request reprint Semiparametric models for cumulative incidence functions
    John Bryant
    Departments of Biostatistics and Statistics, University of Pittsburgh and National Surgical Adjuvant Breast and Bowel Project, 201 N Craig Street, Suite 350, Pittsburgh, Pennsylvania 15213, USA
    Biometrics 60:182-90. 2004
    ..More surprisingly, they are often nearly as efficient as fully parametric estimators. We illustrate the utility of this approach in the analysis of patients treated for early stage breast cancer...
  25. pmc Mammographic density and breast cancer after ductal carcinoma in situ
    Laurel A Habel
    Division of Research, Kaiser Permanente Medical Care Program, Oakland, CA 94612, USA
    J Natl Cancer Inst 96:1467-72. 2004
    ..Our results provide initial evidence that the risk of second breast cancers may be increased among DCIS patients with highly dense breasts...
  26. ncbi request reprint The ongoing search for the sources of the breast cancer survival disparity
    James J Dignam
    J Clin Oncol 24:1326-8. 2006
  27. ncbi request reprint Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less
    Bernard Fisher
    National Surgical Adjuvant Breast and Bowel Project Biostatistical Center, Division of Pathology, and Breast Committee, Pittsburgh, PA, USA
    J Clin Oncol 20:4141-9. 2002
    ....
  28. ncbi request reprint Family history of pancreatic cancer in a high-risk cancer clinic: implications for risk assessment
    Michael J Hall
    Department of Medicine, Columbia University College of Physicians and Surgeons, Mailman School of Public Health, New York, NY 10032, USA
    J Genet Couns 17:365-72. 2008
    ..In risk assessment for HBOS, identifying a family history of PC should strongly raise the suspicion of an unrecognized BRCA1/2 mutation...
  29. ncbi request reprint Early viewing of noninferiority trials in progress
    James J Dignam
    J Clin Oncol 23:5461-3. 2005

Research Grants1

  1. Obesity and Outcomes After Early Stage Breast Cancer
    James Dignam; Fiscal Year: 2003
    ..These investigations will provide valuable information for current patient management and insights into appropriate prospective interventions to improve breast cancer survivorship. ..